Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-096899
Filing Date
2025-04-25
Accepted
2025-04-25 16:19:43
Documents
21
Period of Report
2025-06-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A d901958ddef14a.htm   iXBRL DEF 14A 613755
6 GRAPHIC g901958dsp004.jpg GRAPHIC 139367
7 GRAPHIC g901958dsp005.jpg GRAPHIC 128264
8 GRAPHIC g901958g02k01.jpg GRAPHIC 30082
9 GRAPHIC g901958g02k02.jpg GRAPHIC 20413
10 GRAPHIC g901958g04a03.jpg GRAPHIC 168995
11 GRAPHIC g901958g04a04.jpg GRAPHIC 167422
  Complete submission text file 0001193125-25-096899.txt   2911499

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aldx-20241231.xsd EX-101.SCH 3750
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aldx-20241231_def.xml EX-101.DEF 2967
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20241231_lab.xml EX-101.LAB 3242
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20241231_pre.xml EX-101.PRE 2147
23 EXTRACTED XBRL INSTANCE DOCUMENT d901958ddef14a_htm.xml XML 237324
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36332 | Film No.: 25874384
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)